What is Wedbush’s Estimate for Nuvation Bio Q1 Earnings?

Nuvation Bio Inc. (NYSE:NUVB) – Investment analysts at Wedbush issued their Q1 2026 earnings per share estimates for Nuvation Bio in a research note issued on Thursday, March 6th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.23) for the quarter. Wedbush has a “Outperform” rating and a $5.00 price target on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Nuvation Bio’s Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.21) EPS.

Several other research analysts have also recently weighed in on NUVB. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target (up from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. HC Wainwright reduced their price target on Nuvation Bio from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $8.00.

Nuvation Bio Trading Down 7.2 %

Shares of NUVB stock opened at $1.88 on Monday. The stock has a 50 day moving average of $2.39 and a 200 day moving average of $2.58. The stock has a market cap of $631.06 million, a P/E ratio of -0.86 and a beta of 1.47. Nuvation Bio has a twelve month low of $1.67 and a twelve month high of $4.16.

Institutional Trading of Nuvation Bio

Institutional investors and hedge funds have recently made changes to their positions in the business. Forum Financial Management LP purchased a new stake in shares of Nuvation Bio in the fourth quarter valued at approximately $29,000. Cerity Partners LLC purchased a new stake in shares of Nuvation Bio in the fourth quarter valued at approximately $31,000. Russell Investments Group Ltd. increased its position in shares of Nuvation Bio by 15,183.7% in the fourth quarter. Russell Investments Group Ltd. now owns 15,895 shares of the company’s stock valued at $42,000 after buying an additional 15,791 shares in the last quarter. Abacus Planning Group Inc. purchased a new stake in shares of Nuvation Bio in the fourth quarter valued at approximately $44,000. Finally, Cibc World Markets Corp acquired a new stake in shares of Nuvation Bio in the fourth quarter worth approximately $45,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.